Generic manufacturers must demonstrate bioequivalence to approved brand-name products
Secondary outcomes included changes in kidney perfusion, erythropoietin, haematocrit, urine albumin/creatinine ratio (UACR) and GFR (measured using technetium-99m) compared with baseline and between treatment groups at week 32
\Convenient Dosing: Once-weekly injection
This pathway is divided into an oxidative phase, which generates NADPH for lipid synthesis, antioxidant defense, in addition to ribulose-5-phosphate and intermediates for the synthesis of amino acids, and in phagocytes, NADPH also supplies NADPH oxidase, indirectly contributing to the production of ROS
Research published on the DAC (Drug Affinity Complex) version and the No DAC version provides comparative data on different GHRH analog strategies